Acetylon Pharmaceuticals
- Company typePrivate
- Founded2008
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Acetylon Pharmaceuticals firmographics
Firmographics- Name
- Acetylon Pharmaceuticals
- Website
- https://acetylon.com
- Company type
- Private
- Founded year
- 2008
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Acetylon Pharmaceuticals industry classification
Industry- Product category
- Epigenetic Oncology Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Acetylon Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Acetylon Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Acetylon Pharmaceuticals product offering
Product offeringCore offering
Acetylon Pharmaceuticals develops and manufactures small molecule drugs that target histone deacetylase (HDAC) enzymes to realize the therapeutic potential of epigenetic modulation. The company's offerings are primarily directed at oncology applications, particularly solid tumors, leveraging precision medicine approaches to gene expression regulation.
Differentiator
Problem solved
Functional benefit
Companies that use Acetylon Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Acetylon Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Acetylon Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Acetylon Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Foghorn Therapeutics: Focused on chromatin biology and dysregulated gene expression in cancer and other diseases. Directly comparable gene-expression-modulation approach via chromatin regulators, in oncology.
- Mirati Therapeutics: Precision oncology company developing targeted therapies against genetically defined cancers. Comparable in oncology focus and small-molecule targeted approach, though mechanism differs (kinase/epigenetic-adjacent targets).
- C4 Therapeutics: Develops targeted protein degraders (dacians) with epigenetic targets in oncology. Comparable as a small-molecule platform company exploiting chromatin/epigenetic biology in cancer, with a more differentiated degrader modality.
- NewLink Genetics: Immuno-oncology company whose pipeline has included HDAC-related combinations and IDO pathway inhibitors. Comparable as a small-cap oncology company exploring epigenetic/immune-modulatory combinations.
Direct peers
- Constellation Pharmaceuticals: Epigenetics-focused oncology company developing small-molecule inhibitors of chromatin-modifying enzymes (EZH2, EZH1, BET). Highly comparable as a small-molecule epigenetics platform targeting gene expression regulation in cancer.
- Karus Therapeutics: Develops HDAC inhibitors and PI3K inhibitors for cancer and inflammation. Directly comparable HDAC mechanism focus, similar early-stage development profile.
- Epizyme: Epigenetics drug developer (now part of Ipsen) focused on EZH2 inhibition for cancer. Same broad category — small-molecule drugs targeting chromatin/epigenetic mechanisms in oncology — and similar scale and stage profile.
- Syndax Pharmaceuticals: Clinical-stage oncology company developing entinostat, an HDAC inhibitor, in combination with immuno-oncology agents. Directly comparable mechanism (HDAC inhibition) and oncology focus, making it the closest therapeutic-area peer to Acetylon.
- TetraLogic Pharmaceuticals: Developed small-molecule HDAC inhibitors for oncology (birinapant and related SMAC mimetic/HDAC programs). Direct HDAC mechanism peer in oncology with comparable size and stage profile.
Broad incumbents
- Bristol Myers Squibb: Global biopharmaceutical company with deep oncology and hematology franchises. Comparable as a broad incumbent acquirer of epigenetics/HDAC assets (Celgene, Acetylon's prior lead investor, was acquired by BMS) and as a competitive large-pharma presence in HDAC-adjacent oncology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Acetylon Pharmaceuticals social profiles
Digital presenceAcetylon Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acetylon Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Acetylon Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acetylon Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acetylon Pharmaceuticals
What does Acetylon Pharmaceuticals do?
Acetylon Pharmaceuticals develops and manufactures small molecule drugs that target histone deacetylase (HDAC) enzymes to realize the therapeutic potential of epigenetic modulation. The company's offerings are primarily directed at oncology applications, particularly solid tumors, leveraging precision medicine approaches to gene expression regulation.
When was Acetylon Pharmaceuticals founded?
Acetylon Pharmaceuticals was founded in 2008. It employs 1 to 10 people.
Where is Acetylon Pharmaceuticals based?
Acetylon Pharmaceuticals is headquartered in Boston, United States, in the North America region.
Who are Acetylon Pharmaceuticals's main competitors?
Emerging players on record are Foghorn Therapeutics, Mirati Therapeutics, C4 Therapeutics and NewLink Genetics. Direct peers are Constellation Pharmaceuticals, Karus Therapeutics, Epizyme, Syndax Pharmaceuticals and TetraLogic Pharmaceuticals. Bristol Myers Squibb is listed as a broad incumbent.
Does Acetylon Pharmaceuticals have an API?
No public API is recorded for Acetylon Pharmaceuticals.
What industry is Acetylon Pharmaceuticals in?
Acetylon Pharmaceuticals's product category is Epigenetic Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.